Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nutra PharmaNPHC Effective Interest Rate on Debt % is 4.05% as of Mar. 2026. The stock has 5 warning signs investors should review.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Nutra Pharma's annualized positive value of Interest Expense for the quarter that ended in Mar. 2026 was $0.40 Mil. Nutra Pharma's average total debt for the quarter that ended in Mar. 2026 was $9.88 Mil. Therefore, Nutra Pharma's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 was 4.05%.
Nutra Pharma (OTCPK:NPHC) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Nutra Pharma Effective Interest Rate on Debt % Related Terms
Nutra Pharma Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for Nutra Pharma's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nutra Pharma Effective Interest Rate on Debt % Chart
NPHC vs UPC, CBIH, SXTC: Effective Interest Rate on Debt % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nutra Pharma Effective Interest Rate on Debt % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Nutra Pharma's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 4.05% mean?
Nutra Pharma (NPHC) has a Effective Interest Rate on Debt % of 4.05% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Nutra Pharma and its competitors.
Is Nutra Pharma's Effective Interest Rate on Debt % too high?
Nutra Pharma's current Effective Interest Rate on Debt % is 4.05%.
How does Nutra Pharma's Effective Interest Rate on Debt % compare to UPC and CBIH?
Nutra Pharma's Effective Interest Rate on Debt % of 4.05% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Drug Manufacturers company?
A good Effective Interest Rate on Debt % depends on the Drug Manufacturers industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Nutra Pharma and its competitors. Nutra Pharma's current Effective Interest Rate on Debt % is 4.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nutra Pharma stock overvalued right now?
Nutra Pharma (NPHC) has a current Effective Interest Rate on Debt % of 4.05%. The current Effective Interest Rate on Debt % is 4.05%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Nutra Pharma (NPHC), the current Effective Interest Rate on Debt % is 4.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nutra Pharma Corp operates as a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases, and pain. It is focused on homeopathic and drug discovery research and clinical development, and has developed four homeopathic drugs for the relief of pain: Nyloxin and Nyloxin Extra Strength, Pet Pain-Away, Equine Pain-Away, and Luxury Feet. Additionally, the company has developed two drug candidates: RPI-78M, to treat neurological diseases and autoimmune diseases; and RPI-MN, to treat viral diseases, including HIV/AIDS and Herpes. Nutra Pharma produces, markets, and distributes its branded products both domestically and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPHC has been successfully added to your 
